会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PROCESS FOR PRODUCING CRUDE THREE-LAYERED NOODLES
    • 生产三层圆筒的方法
    • WO1994015485A1
    • 1994-07-21
    • PCT/JP1993000364
    • 1993-03-25
    • NISSIN SHOKUHIN KABUSHIKI KAISHAYAMASAKI, MasahiroHOUSAI, KoichiroSHIRAHASE, HiromiAKAMATSU, NobuyukiTABUCHI, MichiyukiHIRATA, ToshinariMIYAZAKI, Yoshifumi
    • NISSIN SHOKUHIN KABUSHIKI KAISHA
    • A23L01/16
    • A23L7/11
    • A process for producing crude noodles having nerve, viscoelasticity, smoothness and tackiness unique thereto, resistant to softening upon being dipped in hot water, and preservable at ordinary temperature for long, which process comprises the steps of (1) preparing an outer-layer dough by kneading powdery raw material, such as wheat flour, and water, (2) preparing an inner-layer dough having a pH in a neutral or weakly alkaline range by mixing powdery raw material, such as wheat flour, with alginic acid and/or a salt thereof and an alkaline agent, and kneading the resultant mixture and water, and (3) preparing noodle belts from each of the outer-layer and inner-layer doughs in the conventional manner, combining and rolling the belts into a noodle belt having an outer-layer/inner-layer/outer-layer structure, forming noodle strings therefrom in the conventional manner, gelatinizing the starch component of the wheat flour, treating the resultant strings with an acid solution to adjust the pH of the strings to be in an acidic range, packaging and hermetically sealing the strings, and sterilizing the product by heating, wherein the gelatinization may be conducted at the same time with the treatment with an acid solution.
    • 一种生产具有神经,粘弹性,光滑度和粘性的粗面的方法,其特征在于,浸渍在热水中时耐软化,并且可在常温下长时间保存,该方法包括以下步骤:(1)制备外层面团 通过捏合诸如小麦粉和水的粉末状原料,(2)通过将诸如小麦粉的粉末原料与藻酸和/或其混合物制备具有中性或弱碱性范围的pH的内层面团 其盐和碱性试剂,并将所得混合物和水捏合,(3)以常规方式从每个外层和内层面团制备面条,将带组合并滚动到具有 外层/内层/外层结构,以常规方式形成面条,使小麦粉的淀粉成分糊化,用酸溶液处理所得的串,调节 串的pH处于酸性范围,包装并密封线,并通过加热对产品进行灭菌,其中糊化可以在用酸溶液处理的同时进行。
    • 2. 发明申请
    • HIV IMMUNOTHERAPEUTICS
    • 艾滋病毒免疫疗法
    • WO1993004090A1
    • 1993-03-04
    • PCT/US1992007111
    • 1992-08-24
    • NISSIN SHOKUHIN KABUSHIKI KAISHAOHNO, Tsuneya
    • NISSIN SHOKUHIN KABUSHIKI KAISHA
    • C07K15/28
    • C07K16/1063A61K38/00C07K2317/24C07K2317/734
    • The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gp120 protein or its precursor gp160 protein comprising the amino acid sequence set out in SEQ ID NO: 1, G-P-G-R, and characterized by their capacity to neutralize, in vitro, the infection of H9 cells by live HIV-1 strains MN and IIIB as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma A.T.C.C. HB 10726 is fruther characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV-1 infected cells. Pharmaceutical compositions of the invention are projected to be useful in the passive immunization treatment of animals, especially humans, susceptible to or infected with HIV-1.
    • 本发明提供与HIV-1 gp120蛋白或其前体gp160蛋白特异性免疫反应的单克隆抗体,其包含SEQ ID NO:1所示的氨基酸序列,GPGR,其特征在于其体外中和 通过逆转录酶,p24,MT-2和合胞体形成测定法测定的活HIV-1株MN和IIIB对H9细胞的感染。 目前优选的分离自小鼠/小鼠杂交瘤A.T.C.C.的抗体NM-01。 HB 10726的特征在于其介导HIV-1颗粒的补体依赖性病毒分解和HIV-1感染细胞的抗体依赖性细胞毒性的能力。 预计本发明的药物组合物可用于对易感染或感染HIV-1的动物,特别是人的被动免疫治疗。
    • 5. 发明申请
    • HIV IMMUNOTHERAPEUTICS
    • 艾滋病毒免疫疗法
    • WO1994004574A1
    • 1994-03-03
    • PCT/US1993007967
    • 1993-08-24
    • NISSIN SHOKUHIN KABUSHIKI KAISHAOHNO, Tsuneya
    • NISSIN SHOKUHIN KABUSHIKI KAISHA
    • C07K15/28
    • C07K16/1063A61K38/00C07K2317/24C07K2317/34C07K2319/00C07K2319/02
    • The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gp120 protein or its precursor gp160 protein comprising the amino acid sequence set out in SEQ ID NO: 1, G-P-G-R, and characterized by their ability to neutralize, (in vitro), the infection of H9 cells by live HIV-1 strains MN and IIIB as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC HB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV-1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hydridoma cell line ATCC HB 10726 are specifically disclosed. Pharmaceutical compositions of the invention are projected to be useful in the passive immunization treatment of animals, especially humans, susceptible to or infected with HIV-1.
    • 本发明提供了与HIV-1 gp120蛋白或其前体gp160蛋白特异性免疫反应的单克隆抗体,其包含SEQ ID NO:1所示的氨基酸序列,GPGR,其特征在于其中和(体外) ,通过逆转录酶,p24,MT-2和合胞体形成测定法测定的活HIV-1菌株MN和IIIB对H9细胞的感染。 从小鼠/小鼠杂交瘤ATCC HB 10726分离的目前优选的抗体NM-01的特征还在于其介导HIV-1颗粒的补体依赖性病毒分解和HIV-1感染细胞的抗体依赖性细胞毒性的能力。 具体公开了包含由抗体水解细胞系ATCC HB 10726产生的单克隆抗体的至少一个互补决定区的氨基酸序列的人抗体可变区的抗体。 预计本发明的药物组合物可用于对易感染或感染HIV-1的动物,特别是人的被动免疫治疗。